Patient characteristics | Cohort M12 (N = 229) | Cohort M24 (N = 277) |
---|---|---|
Characteristics at ART start | Â | Â |
   Women (%) | 151 (65.9) | 173 (62.4) |
   Median age, years [IQR] | 36.8 [32.0–42.3] | 36.5 [30.8–42.6] |
   ARV naïve (%)* | 225 (98.2) | 273 (98.6) |
   Median follow-up before ART, months [IQR] | 6.2 [3.9–11.4] | 3.7 [1.8–7.7] |
   First ART regimen prescribed d4T/3TC/NVP | 226 (98.7) | 265 (95.7) |
   WHO stage 3 or 4 (%) | 201 (87.7) | 246 (88.8) |
   Body mass index <17 kg/m2 (%) | 38 (17.8); n = 214 | 43 (16.8); n = 256 |
   CD4 cell count, cells/mm3 | n = 133 | n = 239 |
Median [IQR] | 100 [45–147] | 93 [40–144] |
<50 (%) | 36 (27.1) | 73 (30.5) |
Characteristics at time of survey | Â | Â |
   Non-cumulative WHO stage at survey (%) | n = 223 | n = 267 |
Asymptomatic | 136 (61.0) | 160 (59.9) |
Stage 1 or 2 | 63 (28.2) | 86 (32.2) |
Stage 3 or 4 | 24 (10.8) | 21 (7.9) |
   Body mass index, kg/m2 |  |  |
Median [IQR] | 20.4 [18.9–22.0] | 20.8 [19.0–22.5] |
<18.5 kg/m2 (%) | 43 (18.8) | 52 (18.7) |
   Median weight gain since ART start, kg [IQR] | 3 [1–6] | 2 [0–7] |
   ARV-clinical related symptoms (%) |  |  |
Asthenia | 70 (30.7) | 84 (30.3) |
Digestive disorders | 132 (57.6) | 146 (52.7) |
Neurological disorders | 102 (44.5) | 111 (40.1) |
Dermatological disorders | 70 (30.6) | 84 (30.3) |
Morphological disorders | 39 (17.0) | 72 (26.0) |
   CD4 cell count, cells/mm3 |  |  |
Median [IQR] | 223 [163–308] | 238 [172–321] |
<200 (%) | 92 (40.2) | 100 (36.1) |
Median gain since ART start [IQR] | +115 [59–170] | +139 [75–215] |
   Pills taken in last 4 days (%) |  |  |
Good adherence | 200 (87.3) | 258 (93.1) |
Poor adherence | 29 (12.6) | 19 (6.9) |
   30-day VAS (%) |  |  |
Good adherence | 198 (86.5) | 250 (90.3) |
Poor adherence | 31 (13.5) | 27 (9.7) |
   Plasmatic NVP level (%) | n = 204 | n = 258 |
Low | 39 (19.1) | 32 (12.4) |
Normal | 115 (56.4) | 172 (66.7) |
High | 50 (24.5) | 54 (20.9) |
   Plasmatic EFV level (%) | n = 23 | n = 18 |
Low | 1 (4.4) | - |
Normal | 13 (56.5) | 11 (61.1) |
High | 9 (39.1) | 7 (38.9) |